Prenetics Global (Prenetics Global) Cash And Cash Equivalents : $55.3 Mil (As of Sep. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Prenetics Global Cash And Cash Equivalents?

Prenetics Global's quarterly cash and cash equivalents increased from Mar. 2023 ($166.34 Mil) to Jun. 2023 ($177.18 Mil) but then stayed the same from Jun. 2023 ($177.18 Mil) to Sep. 2023 ($55.25 Mil).

Prenetics Global's annual cash and cash equivalents increased from Dec. 2020 ($14.49 Mil) to Dec. 2021 ($35.29 Mil) and increased from Dec. 2021 ($35.29 Mil) to Dec. 2022 ($146.66 Mil).

Prenetics Global Cash And Cash Equivalents Historical Data

The historical data trend for Prenetics Global's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Prenetics Global Cash And Cash Equivalents Chart

Prenetics Global Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Cash And Cash Equivalents

14.49

35.29

146.66

Prenetics Global Quarterly Data
	Dec19	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Cash And Cash Equivalents	Get a 7-Day Free Trial								144.69	146.66	166.34	177.18	55.25

Prenetics Global Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Prenetics Global (NAS:PRE) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Prenetics Global Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Prenetics Global's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Prenetics Global (Prenetics Global) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Prenetics Global Ltd (NAS:PRE) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

N/A

Address

Unit 701-706, K11 Atelier King’s Road, 728 King’s Road, Quarry Bay, Hong Kong, HKG

Website

https://www.prenetics.com

Prenetics Global Ltd is a diagnostic and genetic testing company. It is a genomics and precision oncology company that has devised a method to integrate early detection for cancer, targeted therapy and direct-to-consumer genetic testing services into one comprehensive platform. It operates in two segments. The prevention segment includes the design & sale of genetics testing (including update services) & stool-based DNA tests for early colorectal cancer screening. The diagnostic segment includes the sale of COVID-19 testing services & products and precision oncology services. The majority of revenue is from the diagnostics segment. Geographically, it operates in Hong Kong and the United Kingdom, out of which the majority is from Hong Kong.